Item 8.01 Other Events.
On August 5, 2020, IMAC Holdings, Inc. (the "Company") issued a press release
announcing the approval by the United States Food and Drug Administration (the
"FDA") of the Company's investigational new drug application, which IMAC
submitted in May 2020, for the use of umbilical cord-derived allogenic
mesenchymal stem cells for the treatment of bradykinesia, or the gradual loss
and slowing down of spontaneous body movement, due to Parkinson's disease.
Pursuant to the FDA's approval, the Company anticipates beginning a phase 1
clinical trial of its stem cell treatment within 30 days. A copy of the press
release is attached hereto as Exhibit 99.1 and is incorporated herein by
Cautionary Note Regarding Forward-Looking Statements
The information contained in this Current Report on Form 8-K and the exhibits
attached hereto contain "forward-looking" statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including, without limitation,
statements related to the benefits of the Transaction. The words "intend,"
"may," "should," "would," "expect," "plan," "anticipate," "believe," "estimate,"
"predict," "potential" or "continue" or the negative of these terms or other
comparable terminology are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying words.
While the Company believes its plans, intentions and expectations reflected in
those forward-looking statements are reasonable, these plans, intentions or
expectations may not be achieved. The Company's actual results, performance or
achievements could differ materially from those contemplated, expressed or
implied by the forward-looking statements. For information about the factors
that could cause such differences, please refer to the Company's filings with
the U.S. Securities and Exchange Commission. Given these uncertainties, you
should not place undue reliance on these forward-looking statements. The Company
assumes no obligation to update any forward-looking statement.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Description
99.1 Press Release, dated August 5, 2020.
© Edgar Online, source Glimpses